Highbridge Capital Management’s Quest Diagnostics DGX Stock Holding History

Highbridge Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,900	Closed	-$209K	–	575
2018 Q2	$209K	Buy	+1,900	New	+$198K	﹤0.01%	814
2016 Q1	–	Sell	-16,200	Closed	-$1.15M	–	1553
2015 Q4	$1.15M	Buy	+16,200	New	+$1.09M	0.02%	700
2015 Q2	–	Sell	-5,500	Closed	-$422K	–	1460
2015 Q1	$422K	Buy	5,500 +2,500	+83%	+$179K	0.01%	1014
2014 Q4	$201K	Buy	+3,000	New	+$189K	﹤0.01%	1065
2014 Q2	–	Sell	-4,400	Closed	-$255K	–	1105
2014 Q1	$255K	Buy	+4,400	New	+$236K	﹤0.01%	902

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

Highbridge Capital Management's DGX Position: Q1 2018 in Review

Highbridge Capital Management sold out of Quest Diagnostics (DGX) in Q1 2018, closing a stake of 116,169 shares — an estimated $11.4M sold.

Highbridge Capital Management first reported a position in DGX in Q4 2013 and held it in 4 quarters. The position peaked at $43.3M in Q4 2013. 652 funds tracked by Wall St. Rank hold DGX as of Q1 2018.

Highbridge Capital Management reported no remaining Quest Diagnostics position as of Q1 2018 after selling out during the quarter.
Highbridge Capital Management sold 116,169 Quest Diagnostics shares in Q1 2018, an estimated $11.4M.
Highbridge Capital Management first reported a position in Quest Diagnostics in Q4 2013 and held it in 4 quarters.
Highbridge Capital Management's Quest Diagnostics position peaked at $43.3M in Q4 2013.
652 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.